anti-CD3+glycolipid / Harvard Medical School, Hadassah Medical Organization - LARVOL DELTA

Demonstration of the antitumor activity of the INKT agonist ABX196, a novel enhancer of cancer immunotherapy, in melanoma and hepatocarcinoma mouse models. (PubMed, Mol Cancer Ther) - "In the melanoma model, immune response evaluation included immunofluorescence staining and detection by flow cytometry to identify anti-CD45, anti-CD8, anti-CD4, anti-CD3, anti-CD19, anti-FoxP3, CD1d tetramer, and anti-PD-1 markers. A synergistic combination effect was apparent when interferon-γ was measured in peripheral blood, indicating sustained activation of iNKT cells. In both models, the anti-tumor effects were associated with a generation of a more advantageous T-effector to Treg cell ratio within the tumor, which could lead to in the proliferation and accumulation of cells that would otherwise be anergized."

IO biomarker • Journal • Preclinical • Hepatocellular Cancer • Hepatology • Immune Modulation • Inflammation • Melanoma • Oncology • Solid Tumor • CD8 • FOXP3 • IFNG • PD-L1